Dr. Yoh Terada is an accomplished executive with extensive experience in both scientific and business leadership roles across the biotechnology and pharmaceutical industries.
He currently serves as Chief Scientific Officer and Board Member at Alivexis, Inc., a Japan- and US-based biotech company advancing multiple preclinical programs in oncology and immunology through proprietary simulation technology and AI-driven discovery.
Since the company's operational inception in 2018, Dr. Terada has played a central role in building Alivexis’ R&D pipeline and establishing its virtual operations.
He has led fundraising efforts totaling approximately $50 million USD to date and was instrumental in securing Alivexis’ first out-licensing agreement with Melodia Therapeutics for a non-covalent cathepsin C inhibitor targeting neutrophil-driven diseases.
Prior to Alivexis, Dr. Terada spent nearly 20 years at Astellas Pharma, where he held both scientific and business development positions. Most recently, he served as Director at Astellas Innovation Management in Cambridge, MA, overseeing innovation scouting and external partnerships for the R&D organization. He also held a strategic role at Mitobridge, serving as chief liaison to Astellas and leading the establishment and launch of Mitobridge’s discovery portfolio as a scientific role, which ultimately contributed to its $450 million acquisition by Astellas.
Over the course of his career, Dr. Terada has initiated and led more than 30 drug discovery programs across diverse therapeutic areas and has delivered multiple investigational new drug (IND) candidates. One of those discovery programs delivered MLD-151 which Dr. Terada continues to actively support following the licensing agreement with Melodia.
Dr. Terada holds a PhD in Biomedical Science from Tokyo Medical and Dental University (now Tokyo Institute of Science), as well as an M.S. and B.S. in Biological Chemistry from the University of Tokyo.
